Table 2.
Summary of histopathological tumour regression grade scales available in the literature for rectal cancer after neo-adjuvant treatment
TRG scale | Mandard |
(Low no. - More regression)[43] | |
0 | |
1 | Complete regression - absence of residual cancer and fibrosis |
2 | Presence of rare residual cancer |
3 | An increase in the number of residual cancer cells, but predominantly fibrosis |
4 | Residual cancer outgrowing fibrosis |
5 | Absence of regressive changes |
TRG scale | Modified Mandard (Ryan) |
(Low no. - More regression)[37] | |
0 | |
1 | TRG 1 and 2 of the Mandard scale |
2 | TRG 3 of the Mandard scale |
3 | TRG 4 and 5 of the Mandard scale |
4 | |
5 | |
TRG scale | Werner and Hoffler |
(Low no. - More regression)[41] | |
0 | |
1 | 0% viable tumour cells |
2 | < 10% viable tumour cells |
3 | 10%-50% viable tumour cells |
4 | > 50% viable tumour cells |
5 | No regression |
TRG scale | Dworak |
(Low no. - Less regression)[35] | |
0 | No regression |
1 | Dominant tumour mass with obvious fibrosis and/or vasculopathy |
2 | Dominant fibrotic change with few |
tumour cells or groups(easy to find) | |
3 | Very few tumour cells in fibrotic tissue with or without mucous substance |
4 | No tumour cells, only fibrotic mass (total regression or response) |
5 | |
TRG scale | Modified Dworak |
(Low no. - Less regression)[38] | |
0 | No regression |
1 | Regression ≤ 25% of tumour mass (dominant tumour mass with obvious fibrosis and/or vasculopathy) |
2 | Regression > 25%-50% of tumour mass (dominantly fibrotic changes with few tumour cells of groups, easy to find) |
3 | Regression > 50% of tumour mass (very few tumour cells in fibrotic tissue with or without mucous substance) |
4 | Complete (total) regression (or response): no vital tumour cells |
5 | |
TRG scale | AJCC 7th Edition[48] |
0 | Complete-no viable cells present |
1 | Moderate-single cells/small groups of cancer cells |
2 | Minimal-residual cancer outgrown by fibrosis |
3 | Poor-minimal or no tumour kill, extensive residual cancer |
4 | |
5 | |
TRG scale | Memorial Sloan-Kettering (Low no. - Less regression)[47] |
0 | 0%-85% regression |
1 | 86-99% regression |
2 | 100% regression |
3 | |
4 | |
5 | |
TRG scale | Cologne |
(Low no. - Less regression)[40] | |
0 | |
1 | > 50 % Viable rectal tumour cells |
2 | 10%-50% Viable rectal tumour cells |
3 | Near complete regression with < 10% Viable rectal tumour cells |
4 | Complete regression (pathologic complete remission and ypT0) |
TRG scale | Bujko/Glynne Jones |
(Low no. - More regression)[18,44] | |
0 | No cancer cells |
1 | A few cancer foci in less than 10% of tumour mass |
2 | Cancer seen in 10%-50% of tumour mass |
3 | Cancer cells seen in more than 50% of tumour mass |
4 | |
TRG scale | College of American Pathologists[50] |
0 | Complete response: No residual tumour |
1 | Marked response: Minimal residual cancer |
2 | Moderate response: Residual cancer outgrown by fibrosis |
3 | Poor or no response: Minimal or no tumour kill; extensive residual cancer |
4 | |
TRG scale | RCPath system |
(Low no. - More regression)[42] | |
0 | |
1 | No residual cells and/or mucus lakes only |
2 | Minimal residual tumour i.e., microscopic residual tumour foci only |
3 | No marked regression |
4 | |
TRG scale | RCRG system |
(Low no. - More regression)[34] | |
0 | |
1 | Sterilisation or only microscopic foci of adenocarcinoma with marked fibrosis |
2 | Marked fibrosis but macroscopic disease present |
3 | Little or no fibrosis with abundant macroscopic disease |
4 | |
TRG scale | Mod RCRG system |
(Low no. - More regression)[45] | |
0 | |
1 | Macroscopic features may be varied. Microscopy reveals no tumour or < 5% of area of abnormality |
2 | Macroscopic features may be varied. Microscopy reveals combination of viable tumour and fibrosis. Tumour comprises 5%-50% of overall area of abnormality |
3 | Macroscopic or microscopic features may not be significantly different. Over 50% comprises tumour. Some fibrosis may be present but no more than untreated cases |
4 | |
TRG scale | Japanese |
(Low no. - Less regression)[25] | |
0 | No regression |
1a | Minimal effect (necrosis less than 1/3) |
1b | Mild effect (necrosis less than 2/3 but more than 1/3) |
2 | Moderate effect (necrosis more than 2/3 of the lesion) |
3 | No tumour cells |
TRG scale | Ruo |
(Low no. - Less regression)[39] | |
0 | No evidence of response |
1 | 1% to 33% response |
2 | 34% to 66% response |
3a | 67% to 95% response |
3b | 96% to 99% response |
4 | 100% response (no viable tumour identified) |
TRG scale | Junker and Muller |
(Low no. - Less regression)[46] | |
1 | No regression |
2a | > 10% residual tumour cells |
2b | < 10% residual tumour cells |
3 | Total regression (no viable tumour cells) |
TRG scale | Rodel |
(Low no. - Less regression)[36] | |
Poor | TRG 1 and 0 of the Dworak scale |
Intermediate | TRG 2 and 3 of the Dworak scale |
Complete | TRG 4 of the Dworak scale |
TRG scale | Four point scale |
Swellengrebel et al[49] | |
pCR | Pathological complete response without residual primary tumour |
Near pCR | Isolated residual tumour cells/small groups of residual tumour cells |
Response | Stromal fibrosis outgrowing tumour |
No response | No regression or those with stromal fibrosis outgrown by tumour |
TRG scale | Modified Mandard TRGN by Dhadda et al[51] |
TRGN 1 | Complete regression with absence of residual cancer and fibrosis extending through the wall |
TRGN 2 | Presence of rare residual cancer cells scattered through the fibrosis |
TRGN 3 | An increased number of residual cancer cells, but fibrosis is still predominant |